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Abstract 
Tumor-positive resection margins are present in up to 23% of head and neck cancer (HNC) surgeries, as 
intraoperative techniques for real-time evaluation of the resection margins are lacking. In this study, we 
investigated the safety and potential clinical value of fluorescence-guided imaging (FGI) for resection 
margin evaluation in HNC patients. We determined the optimal cetuximab-800CW dose by 
quantification of intrinsic fluorescence values using multi-diameter single-fiber reflectance, single-fiber 
fluorescence (MDSFR/SFF) spectroscopy. 
Methods: Five cohorts of three HNC patients received cetuximab-800CW systemically: three single 
dose cohorts (10, 25, 50 mg) and two cohorts pre-dosed with 75 mg unlabeled cetuximab (15 or 25 mg). 
Fluorescence visualization and MDSFR/SFF spectroscopy quantification was performed and were 
correlated to histopathology. 
Results: There were no study-related adverse events higher than Common Terminology Criteria for 
Adverse Events grade-II. Quantification of intrinsic fluorescence values showed a dose-dependent 
increase in background fluorescence in the single dose cohorts (p<0.001, p<0.001), which remained 
consistently low in the pre-dosed cohorts (p=0.6808). Resection margin status was evaluated with a 
sensitivity of 100% (4/4 tumor-positive margins) and specificity of 91% (10/11 tumor-negative margins).  
Conclusion: A pre-dose of 75 mg unlabeled cetuximab followed by 15 mg cetuximab-800CW was 
considered the optimal dose based on safety, fluorescence visualization and quantification of intrinsic 
fluorescence values. We were able to use a lower dose cetuximab-800CW than previously described, 
while remaining a high sensitivity for tumor detection due to application of equipment optimized for 
IRDye800CW detection, which was validated by quantification of intrinsic fluorescence values. 
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Head and neck cancer (HNC) is the sixth most 
common cancer worldwide, with an incidence of over 
550,000 and around 300,000 cancer-related deaths 
each year [1]. The most common histological subtype 
is head and neck squamous cell cancer (HNSCC), 
accounting for more than 90% of all HNCs. 
Depending on anatomical location, the primary 
treatment of HNSCC consists of surgical resection or 
(chemo)radiotherapy [2-7]. In case of surgical 
treatment, tumor-negative resection margins are 
essential for local control and consequently improve 
survival. A tumor-positive resection margin in head 
and neck oncology is generally defined as viable 
tumor cells within 1 mm of the resection margin. 
Tumor-negative resection margins reduce the need 
for adjuvant treatment, while a tumor-positive 
resection margin often involves treatment with 
cisplatin-based chemo-radiation, which severely 
increases the risk of sequelae. 
Despite improving pre- and intraoperative 
imaging techniques, no accurate clinically approved 
tools are available to discriminate between tumor and 
surrounding non-tumor tissue for real-time margin 
assessment during surgery. Consequently, surgeons 
rely on their experience and visual and tactile 
information alone. Due to the intrinsic limitations of 
the provided information, this contributes to a 
tumor-positive resection margin rate that is reported 
to be as high as 23% in HNSCC [8-10].  
With the development of clinical grade small 
peptides and antibodies conjugated to fluorescent 
dyes, the field of fluorescence-guided imaging (FGI) 
has rapidly evolved and expanded to application in 
several solid tumor types [11-14]. FGI has the 
potential to provide real-time feedback on increased 
receptor expression in cancerous tissue and 
highlighting these cancer cells by binding of 
fluorescent labelled tracers, making it an interesting 
technique for intraoperative margin evaluation. Since 
the first clinical study on FGI in 2011, in which a 
conjugate of folate-FITC was used to visualize 
peritoneal metastasis of ovarian cancer, several 
studies in different tumor types and organs have been 
performed that further demonstrate the potential of 
FGI for discrimination between tumor and healthy 
tissue [13,15-19]. 
A promising target for targeted-FGI in HNSCC 
patients is the endothelial growth factor receptor 
(EGFR). Overexpression of EGFR in HNSCC is 
present in up to 90% of the cases and is associated 
with higher local recurrence and poorer survival rates 
[20,21]. Two early phase clinical trials on FGI in 
HNSCC patients have already been performed, 
investigating a monoclonal antibody (cetuximab and 
panitumumab respectively) targeting EGFR, which 
was conjugated to the near-infrared (NIR) fluoro-
phore IRDye800CW [15,22].  
Since external factors such as ambient light, 
angle of imaging and distance from tissue to imaging 
device all may influence imaging results severely 
[23,24], it is hypothesized that evaluation of the 
excised specimen might be interesting, with 
encouraging results reported previously using 
panitumumab-800CW [25,26]. However, although 
tissue absorption and scattering are minimized in the 
NIR spectrum (700-900 nm), these phenomena affect 
fluorescence imaging resulting in higher signals in 
highly scattering tissue or lower signals in areas that 
contain high concentrations of blood or in crusts of 
necrotic tissue for example. 
 To date, correction for these factors is lacking for 
FGI in HNC surgery, which might cause different 
interpretation of fluorescence results within and 
between patients and centers. In order to tackle the 
aforementioned technical issues, we applied multi- 
diameter single-fiber reflectance and single-fiber 
fluorescence (MDSFR/SFF) spectroscopy to correct 
for tissue optical properties in order to determine the 
quantitative intrinsic fluorescence values [23,27-30]. 
The design of our study was adapted based on earlier 
reports that a pre-dose of unlabeled cetuximab 
improved cetuximab-800CW FGI results, most likely 
due to increased off-target receptor occupancy and 
tissue sequestration [31]. However, to date adminis-
tration of a single flat-dose of cetuximab-800CW has 
not been compared to administration of cetuximab- 
800CW preceded by an unlabeled dose of cetuximab, 
nor has quantification of intrinsic fluorescence values 
been included in dose-escalating studies to find the 
optimal cetuximab-800CW dose for FGI. 
In this study, we determined the safety and 
optimal dosing regimen of cetuximab-800CW for FGI 
through real-time intraoperative fluorescence visuali-
zation and quantification of intrinsic fluorescence 
values and evaluated the clinical added value of 
back-table FGI for resection margin assessment. 
Methods 
Clinical Trial design 
This phase-I safety, feasibility and dose- 
escalation study was performed at the department of 
Oral & Maxillofacial Surgery of the University 
Medical Center Groningen (UMCG, Groningen, The 
Netherlands). Fifteen patients with histopathological 
proven HNSCC that were scheduled for tumor 
resection were included. Patients were identified after 
the HNC multidisciplinary tumor board agreed on 
surgery as the primary treatment modality. Written 





and signed informed consent was obtained prior to 
any study-related procedure. The study was 
approved by the Institutional Review Board (IRB) of 
the UMCG (METc 2016/395) and conducted 
according to the Dutch Act on Medical Research 
involving Human Subjects (WMO) and the principles 
of the Declaration of Helsinki (adapted version 
Fortaleza, Brazil, 2013). The trial was registered at 
www.clinicaltrials.gov (NCT03134846). 
We performed an adapted phase-I dose- 
escalation study (5x3 design) adhering to the FDA 
guidelines (Guidance for Industry, Developing 
Medical Imaging Drug and Biological Products, Part 2 
Clinical Indications). All fifteen patients received 
cetuximab-800CW four days prior to surgery. The 
dose-escalation study was divided into two parts. Part 
I involved a single intravenous (IV) administration of 
cetuximab-800CW (10, 25 or 50 mg single-dose). After 
an interim analysis, part II commenced, in which 
patients received 75mg unlabeled cetuximab IV 1h 
prior to IV administration of cetuximab-800CW (15 or 
25 mg). This 1 h interval was based on previous 
studies on pre-dosing with cetuximab [15,31]. The 
study workflow is depicted in Figure 1.  
GMP synthesis of cetuximab-800CW 
Clinical grade cetuximab-800CW (peak excita-
tion and emission wavelength of 778 and 795 nm 
respectively) was produced in the Good 
Manufacturing Practice (GMP) facility of the UMCG 
and released by a certified Qualified Person (QP). A 
detailed description of the production process has 
been described previously [32]. Briefly, commercially 
available cetuximab (Erbitux®) 5 mg/mL was 
conjugated to the near-infrared fluorescence dye 
IRDye800CW (LI-COR Biosciences, Lincoln, NE, USA) 
and purified using PD-10 buffer exchange columns 
(GE Healthcare, Chicago, IL, USA). Cetuximab- 
800CW was formulated in a sodium-phosphate buffer 
at a concentration of 1 mg/mL. All study patients 
received cetuximab-800CW through a single IV bolus 
injection. 
Safety measurements 
Patients underwent a medical screening 
procedure before enrollment in the study, consisting 
of measurements of vital signs, a 12-lead electro-
cardiogram (ECG) and laboratory tests (including a 
serum pregnancy test for woman of childbearing 
potential). Once enrolled, an ECG was performed 1 h 
after administration of cetuximab-800CW. Vital signs 
were measured before and after tracer administration 
(directly and after 1 h). Patients were asked for signs 
and symptoms before and after tracer administration 
(directly and after 1 h). After surgery, standard 
postoperative (outpatient clinic) visits were 
performed within two weeks. Adverse event 
assessment was performed according to the National 
Cancer Institute Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.0. Serious adverse 
events (SAE), if present, were reported to the IRB, the 
independent Data Safety Monitoring Board (DSMB) 
and the Dutch central committee on research 
involving human subjects (CCMO). SAE’s were 
followed up until fully resolved or a stable medical 
situation was achieved. 
Surgical procedure (standard of care) 
All patients underwent tumor resection 
according to standard surgery protocols. Depending 
on preoperative TNM staging, a sentinel lymph node 
biopsy (lymph node mapping using the peritumoral 
 
 
Figure 1. Study workflow. Five cohorts of three HNC patients received cetuximab-800CW systemically: three single dose cohorts (10, 25, 50 mg) and two cohorts 
pre-dosed with 75 mg unlabeled cetuximab (15 or 25 mg). Fluorescence visualization was performed before and after excision of the tumor in vivo. Subsequently, back-table 
fluorescence-guided imaging of the fresh surgical specimen was performed to evaluate the resection margin status. Visualization and quantification of fluorescence was performed 
during all subsequent steps of standard histopathological processing and correlated to histopathology. Abbreviations: FFPE: Formalin-Fixed Paraffin Embedded, H/E: Hematoxylin 
and Eosin. *75 mg unlabeled cetuximab is administered one hour prior to cetuximab-800CW administration. 





administration of Technetium-99m-labelled nanocol-
loid one day prior to surgery and subsequent 
intraoperative detection using a gamma-probe) or a 
lymph node dissection was performed. Based on our 
previous experience in the UMCG with application of 
FGI, there was minimal interference with standard of 
care [13,16,18]. 
In vivo fluorescence imaging 
Surgical procedures were performed according 
to standard of care and were prioritized over any 
study-related procedures. Visualization of 
fluorescence was performed prior to incision of the 
primary tumor and directly after excision of the 
surgical wound bed. During fluorescence imaging, 
the ambient light in the surgical theatre was dimmed 
to minimize influence on fluorescence imaging 
results. The use of methylene blue in sentinel node 
procedures was avoided. The use of fluorescent skin 
markers and (green) fluorescent sterile drapes was 
minimalized to prevent interference with fluorescence 
imaging results [18]. It should be noted that in vivo 
imaging of the tumor in the oral cavity is only 
performed to visualize fluorescence and observe 
fluorescence patterns. All measurements of 
fluorescence intensities are performed on the excised 
specimen. 
Fluorescence cameras 
Two intraoperative fluorescence imaging devices 
were used in this study to detect cetuximab-800CW. 
Depending on the location of the tumor, either a 
custom build fluorescence endoscopy platform (Surg-
Vision BV., Groningen, The Netherlands) attached to 
a flexible nasendoscope (Karl Storz, Tuttlingen, 
Germany), or an intraoperative fluorescence camera 
system (Explorer Air®, SurgVision BV., Groningen, 
The Netherlands) was used during surgery. Both 
systems provide real-time simultaneously fluorescence 
and white light (color) images and videos. 
Fluorescence is excited by either a NIR laser 
(fluorescence nasendoscopic system) or light emitting 
diodes (Explorer Air®), both of which have an 
excitation peak specific for cetuximab-800CW 
detection. Filtered white light is used to provide 
illumination for the color images. A software user 
interface is provided to allow the user control over 
camera settings and to display the color and 
fluorescence images. As output, both snapshots as 
well as videos can be recorded and stored in TIFF 
format. The working distance of the imaging system 
above the surgical field was set at 3-5 cm for the 
fluorescence nasendoscopic system and 20 cm for the 
Explorer Air®. All images were initially obtained with 
a fluorescence exposure time of 50 ms and a set gain 
of 300, which could be adjusted depending on 
fluorescence imaging results. 
Back-table FGI and specimen processing 
Immediately after excision, the surgical speci-
men was marked using sutures for orientation and 
cross-correlation with histopathology. Subsequently, 
back-table FGI was performed of all resection planes 
of the fresh surgical specimen. Two back-table FGI 
devices were used in parallel, the Explorer Air® 
coupled to a closed-field imaging box (Vault®, 
SurgVision BV., Groningen, The Netherlands) and a 
PEARL-trilogy ® imager with a larger adapted 
sample stage (LI-COR BioSciences Inc., Lincoln, NE, 
USA). The Pearl-trilogy® detects fluorescence using a 
CCD camera in the NIR wavelength (peak excitation 
785 nm, peak emission 820 nm). The field of view of 
11.2 cm x 8.4 cm and the focus point can be adjusted 
based on specimen height. Fluorescence was scored at 
the resection margin by physicians blinded for 
histology results and scored positive if the TBR was 
higher than two (the specimen was used as its own 
internal control). 
 After back-table FGI, the specimen was formalin 
fixed for at least 24 h, depending on specimen size, 
after which the specimen was inked to mark resection 
margins on final histopathology with black and blue 
ink.  
The formalin-fixed surgical specimen was 
serially sliced into approximately 0.4 cm thick tissue 
slices. White-light images were acquired during and 
directly after tissue slicing for orientation purposes. 
After slicing, fluorescence imaging was performed on 
both sides of each tissue slice using the PEARL- 
trilogy®. Subsequently, a pathologist blinded for the 
fluorescence images selected regions of interest based 
on gross examination by visual inspection and 
palpation, which were further embedded in paraffin 
blocks for standard histopathological analysis. In case 
of the presence of bone, tissue was decalcified before 
further processing. A standardized workflow was 
used in order to cross-correlate final histopathology 
results with recorded fluorescence images of tissue 
slices of interest [18]. Subsequently, hematoxylin and 
eosin (H/E) staining was performed on 4 μm tissue 
sections for histopathological analysis and analyzed 
by a board-certified pathologist blinded for 
fluorescence imaging results. A tumor-positive 
resection margin was defined as viable tumor tissue 
within 1 mm of the resection margin according to 
European guidelines in HNSCC treatment [33]. 
Ex vivo MSDFR/SFF spectroscopy 
The MDSFR/SFF spectroscopy device acquires 
two reflectance spectra by using two different optical 





fibers and subsequently one raw fluorescence 
spectrum, as described previously [18]. Briefly, the 
scattering and absorption coefficients are determined 
from the two reflectance spectra. These are then used 
to calculate the intrinsic fluorescence values (Q·µfa,x) 
of cetuximab-800CW, by correcting the raw 
fluorescence spectrum for the calculated tissue optical 
properties [34]. Intrinsic fluorescence values (Q·µfa,x) 
of cetuximab-800CW are defined as a product of the 
quantum efficiency across the emission spectrum, 
Q[-], where Q is the fluorescence quantum yield of 
IRDye-800CW and µaf [mm-1] is the tracer absorption 
coefficient at the excitation wavelength. The data is 
collected using direct contact measurements. All 
measurements were repeated in triplicate and median 
values were calculated per measurement location.  
 We calculated the concentration of IRDye800CW 
based on an assumed extinction coefficient (31120.4 
mm-1), fluorescence quantum yield (0.09) and the 
cetuximab-800CW load factor (1:2) for each cohort 
[12] ex vivo in the tissue specimens. 
Ex vivo validation of fluorescence intensities 
and localization 
PEARL-trilogy® images of tissue slices that 
contained tumor tissue and non-tumor tissue were 
used to calculate the mean fluorescence intensity 
(MFI) of both tumor and non-tumor tissue.  
A board-certified pathologist, blinded from the 
fluorescence images, drew region of interests (ROI) of 
areas that contained tumor on 4 μm H/E slides and 
subsequently overlaid on the corresponding tissue 
slice. MFIs were calculated based on these ROIs on the 
tissue slices of both tumor tissue and non-tumor 
tissue (i.e. all tissue in the tissue slice diagnosed as 
non-tumor tissue). A tumor-to-background-ratio 
(TBR) was calculated by dividing tumor ROI (MFI 
tumor) with the background ROI (MFI non-tumor 
tissue) per tissue slice. Median TBR values were 
calculated on a per patient base.   
 Immunohistochemical analysis was performed 
on 4 μm thick tissue sections which contained tumor 
and non-tumor tissue to correlate fluorescence 
intensities with EGFR expression (VENTANA 
Benchmark Ultra anti-EGFR (Clone 3C6), Roche, 
Basel, Switzerland). The EGFR-membrane expression 
was evaluated following a pre-defined scoring system 
(0, +, ++ or +++) by a board-certified pathologist.  
An inverted microscope (DMI6000B, Leica 
Biosystems GmbH, Wetzlar, Germany) was used for 
fluorescence microscopy with a pixel size of 6.45 µm 
and a field of view of 120 × 120 mm. To optimize NIR 
visualization, the microscope was equipped with a 
NIR LED light source ranging up to 900 nm (X-Cite 
200DC, Excelitas Technologies, Waltham, MA, USA), 
a NIR filter set (microscope two band- pass filters 850–
890 m–2p and a long-pass emission filter 
HQ800795LP; Chroma Technology Corp, Bellows 
Falls, VT, USA) and a monochrome DFC365 FX 
fluorescence camera (1.4 M Pixel CCD, Leica 
Biosystems GmbH). An acquisition time of 12 s was 
used for images of the 800 nm channel. 
Cetuximab-800CW tracer integrity  
Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) was performed both on 
blood samples of the included patients collected on 
day four and on lysate of fresh frozen tumor tissue to 
ensure intactness of the cetuximab-800CW conjugate, 
as previously described (ProSieve® Quadcolor™ 
Protein Markers, Lonza Rockland Inc., ME, USA and 
Mini-Protean TGX Precast Protein Gel, Bio-Rad 
Laboratories Inc., California, USA) [18,35]. Results 
were compared with labeled and unlabeled 
cetuximab. The gel was scanned with the Odyssey 
CLX® flatbed scanner (LI-COR Biosciences Inc. 
Lincoln, NE, USA) at the 800 nm channel. 
Statistical analysis 
Descriptive statistics were performed on the 
patient demographics. MFI was calculated using 
ImageJ Fiji (version 2.0.0-rc-68/1.52h) as total counts 
per ROI pixel area in both tumor and non-tumor 
tissue. Data was tested for Gaussian distribution 
using Anderson-Darling and Shapiro-Wilk test; none 
of the data was normally distributed. Differences 
between paired and unpaired data was tested using a 
Wilcoxon test and Mann-Whitney test respectively. 
Data is presented as median values with interquartile 
ranges. For statistical analysis and graph design, 
GraphPad Prism (version 8.0, GraphPad Software Inc, 
San Diego, California, USA) was used.  
Results 
Fifteen patients with HNSCC were included in 
this study. The age of the patients ranged from 48 to 
86 years. Administration of cetuximab-800CW was 
considered to be well tolerated in all dose-cohorts, 
with five possibly related adverse events throughout 
the study that were all limited to CTCAE grade I 
events (Table 1 and Table S1). The grade II event (i.e. 
bronchospasm) was considered not to be imaging 
agent related but iatrogenic since the administration 
speed was accidently set 10x higher than 
recommended. 
Evaluation of resection margin status  
Four patients were diagnosed with a 
tumor-positive resection margin (i.e. <1 mm) based on 
standard histopathology (Table 1). During back-table 





FGI of the fresh surgical specimens, all four 
tumor-positive resection margins were correctly 
identified (sensitivity 100%; Figure 2 and Table 2). In 
vivo visualization of the wound bed did not show 
remaining fluorescent lesions. This was in line with 
final histopathology, since all four tumor-positive 
resection margins were based on the presence of 
viable tumor cells within 0.3-1 mm of the resection 
margin, suggesting there was no residual tumor in the 
wound bed. 
Eleven out of fifteen patients were diagnosed 
with a tumor-negative resection margin upon final 
histopathology (Table 1). Back-table FGI of the fresh 
surgical specimens showed no fluorescent lesions on 
the resection margins in 10/11 patients (specificity 
91%; Table 2). The remaining resection margin (2 mm) 
was evaluated as tumor-positive based on a 
fluorescent lesion (Figure S1). 
In addition, one satellite tumor lesion was 
detected during in vivo FGI, which was located 
anterior of the main tumor lesion (Figure 3B, yellow 
arrows), highlighting the potential added value of 
real-time intraoperative FGI. Fluorescence imaging 
procedures prolonged the standard procedure with 
approximately 10 min and did not interfere with the 
standard of care. Difficult and easily accessible tumors 
and surgical cavities could be visualized in vivo using 
the flexible nasendoscopic camera and the Explorer 
Air® respectively (Figure 3A-B and Video S1).  
 













75 mg CTX + 
15 mg CTX-800CW 
N=3 
75 mg CTX + 
25 mg CTX-800CW 
N=3 
Age (mean years, range) 68 (59-73) 62 (56-71) 63 (48-86) 63 (50-78) 55 (49-64) 
Males (number, percentage) 2 (53%) 3 (100%) 1 (33%) 1 (33%) 1 (33%) 
Weight (mean kg, range) 79 (45-104) 77 (57-97) 78 (93-97) 97 (81-140) 82 (58-122) 
Safety      
Grade I 2 2 0 1 0 
Grade II 0 0 0 1 0 
Tumor histology      
HNSCC 3 3 3 3 3 
Size      
Max Diameter (mean ±SD mm) 34 (±20) 20 (±7.5) 18 (±7.0) 30 (±11) 26 (±18) 
Depth of Invasion (mean ±SD mm) 11 (±3.6) 6 (±1.4) 4 (±0.8) 5 (±3.1) 6 (±5.1) 
Surgical margin*      
Tumor-negative 2 2 2 2 3 
Tumor-positive 1 1 1 1 0 
Patient and surgical specimen characteristics are depicted per cohort. Potential related adverse events are scored according to the Common Terminology Criteria for Adverse 
Events. *Tumor-negative margin: >5 mm; tumor-positive surgical margin: <1 mm. Abbreviations: CTX: Cetuximab. 
 
 
Figure 2. Representative example of back-table FGI of a tumor-positive resection margin. Back-table fluorescence-guided imaging (FGI) of a fresh surgical 
specimen, with a clearly localized increased fluorescent lesion, indicating a tumor-positive ventral resection margin of a tumor located on the floor of the mouth upon final 
histopathology. The tumor-positive resection margin on the tissue slice and section (red arrows) correspond to the location on the fresh surgical specimen (yellow lines). 
Abbreviations: H/E: Hematoxylin and Eosin. EGFR: Endothelial Growth Factor Receptor. 





Visualization and quantification of 
cetuximab-800CW fluorescence 
To objectivate the potential of cetuximab-800CW 
for the discrimination of tumor tissue versus 
non-tumor tissue, we first calculated the tumor 
fluorescence of the ROI of tissue slices (N=61). Here, 
significantly higher fluorescence intensities in tumor 
tissue compared to non-tumor tissue were detected 
for all cohorts (TBR 10 mg: 1.61±0.93, p=0.0312; 25 mg: 
2.02±0.55, p=0.0078; 50 mg: 1.81±0.32, p<0.0001; 75 + 
15 mg: 3.06±0.43, p=0.0010; 75 + 25 mg: 3.10±2.53, 
p=0.0005; Figure 4A-B and Table 3), with increasing 
TBRs in the pre-dosed cohorts. To further validate 
these findings, quantification of the intrinsic 
fluorescence values by MDSFR/SFF on tissue slices 
(N=46) confirmed these findings in all dose-cohorts 
(TBRs 10 mg: 2.86±0.29, p=0.0312; 25 mg: 1.99±1.62, 
p=0.0078; 50 mg: 1.48±0.52, p<0.0001; 75 + 15 mg: 
2.50±0.19, p=0.0010; 75 + 25 mg: 2.81±1.27, p=0.0005; 
Figure 4C and Table 3). 
 A dose-dependent increase in background 
fluorescence in the single-dose cohorts was observed 
using both fluorescence intensities of the tissue ROI of 
the fluorescence images (10 mg vs. 25 mg: p=0.0006, 25 
mg vs. 50 mg: p<0.0001) and quantification of intrinsic 
fluorescence values (10 mg vs. 25 mg: p<0.0001, 25 mg 
vs. 50 mg: p<0.0001), whereas this remained 
consistently low in the cohorts pre-dosed with 
unlabeled cetuximab, without a significant difference 
between both cohorts (p=0.4320 and p=0.6808 for 
fluorescence imaging and MDSFR/SFF spectroscopy 
respectively). Median intrinsic fluorescence values in 
non-tumor tissue were significantly lower in the 75 + 
25 mg cohort compared to the 25 mg single-dose 
cohort (0.0101 mm-1 vs. 0.0131 mm-1, p=0.0096, 
respectively). 
Fluorescence intensities of tumor tissue 
increased with increasing doses in the single dose 
cohorts (10 mg vs. 25 mg: p=0.0044, 25 mg vs. 50 mg: 
p<0.0001), but not in the in the pre-dose cohorts (75 + 
15 mg vs. 75 + 25 mg: p=0.8959) using tissue 
fluorescence of the ROI of tissue slices. Quantification 
of intrinsic fluorescence values by MDSFR/SFF 
spectroscopy showed no dose-dependent increase (10 
mg vs. 25 mg: p=0.8291, 25 mg vs. 50 mg: p=0.2351, 75 
+ 15 mg vs. 75 + 25mg: p=0.7573). 
 








Back-table FGI positive 4 1 5 
Back-table FGI negative 0 10 10 
Total 4 11 15 
All four tumor-positive resection margins were correctly identified using 
back-table fluorescence-guided imaging (FGI) of the fresh surgical specimens. In 
addition, ten tumor-negative resection margins were correctly identified. One 
tumor-negative resection margin was identified as tumor-positive, based on 
back-table FGI. Abbreviations: FGI: Fluorescence-guided imaging. 
 
Table 3. Ex vivo tumor-to-background ratio per dose cohort. 
Dose-cohort TBR 
Visualization Spectroscopy 
10mg 1.61 ± 0.93 2.86 ± 0.29 
25mg 2.02 ± 0.55 1.99 ± 1.62 
50mg 1.81 ± 0.32 1.48 ± 0.52 
15mg* 3.06 ± 0.43 2.50 ± 0.19 
25mg* 3.10 ± 2.53 2.81 ± 1.27 
Median tumor-to-background ratios shown both for fluorescence visualization 
using a closed-field imaging device and quantification of intrinsic fluorescence 
values using MDSFR/SFF spectroscopy. 
 
 
Figure 3. In vivo fluorescence visualization during surgery. A: Representative fluorescence imaging using the nasendoscopic fluorescence imaging system of a buccal 
HNSCC tumor. B: Representative fluorescence imaging using Explorer Air® fluorescence imaging system of a HNSCC tumor of the tongue. Yellow arrows indicate a separate 
second tumor lesion diagnosed using cetuximab-800CW fluorescence. 






Figure 4. Ex vivo correlation and quantification of cetuximab-800CW fluorescence. A: Tumor tissue is delineated on Hematoxylin and Eosin (H/E) staining, which 
correlates to the fluorescence imaging results on the tissue slices and EGFR expression on tissue slice containing tumor (upper row) and a tumor-positive resection margin 
(middle row), whereas a non-tumor tissue slices shows low fluorescence intensities and no EGFR expression (lower row). Red arrows indicate a tumor-positive margin of 0.3 
mm. B: Tumor tissue showed significantly increased fluorescence intensities compared to non-tumor tissue on fluorescence images of tissue slices. C: Intrinsic fluorescence values 
were significantly higher in tumor tissue compared to non-tumor tissue. * 75 mg cetuximab is administered one hour prior to cetuximab-800CW administration. Dots represent 
median intrinsic fluorescence values per measurements location. Error bars represent median values and interquartile range. Abbreviations: H/E: Hematoxylin and Eosin. EGFR: 
Endothelial Growth Factor Receptor. 
 
  After correcting ex vivo fluorescence measure-
ments obtained by MDSFR/SFF spectroscopy for 
tissue optical properties, the intrinsic fluorescence 
values (i.e. corrected) decreased in the majority of 
patients compared to the uncorrected values. 
Scattering and absorption coefficients mainly affected 
non-tumor tissue measurements (Figure S2), resulting 
in higher, although not significant, TBRs when 
comparing MDSFR/SFF spectroscopy TBRs to 
fluorescence imaging TBRs (2.50 ± 1.00vs. 2.13 ± 1.04 
respectively; p=0.9780, Figure S3). 
EGFR immunohistochemistry showed 
expression in 96% of the tumors, in contrast to deeper 
seated non-tumor tissue (e.g. fat, connective tissue 
and muscle tissue; N=27 tissue sections; Figure S4). In 
addition, nineteen tissue sections contained salivary 
glands, of which nine (47%) showed a moderate EGFR 
expression. To further validate cetuximab-800CW 
binding specificity, fluorescence microscopy showed 
cetuximab-800CW was localized around tumor cell 
membranes (Figure 5). 
Cetuximab-800CW integrity 
Cetuximab-800CW integrity was confirmed four 
days after administration in blood samples and tumor 
lysates of fresh surgical specimen samples (Figure S5). 






In this study, the optimal dose of 
cetuximab-800CW appeared to be a dose of 15 mg 
cetuximab-800CW preceded by 75 mg of unlabeled 
cetuximab. Further increasing the cetuximab-800CW 
dose after pre-dosing did not significantly increase the 
tumor-to-background ratios.  
In fluorescence guided imaging, evaluation of 
the resection margin status is most reliably done ex 
vivo, as previous studies of our group and others 
show [18,25,36]. In addition, determining the optimal 
dose ex vivo can be done more reliable since in vivo 
imaging does not allow collection of data in a 
standardized manner which can influence results [23]. 
In the current study, we used ex vivo tissue 
fluorescence intensities of the tissue slices of tumor 
and adjacent non-tumor tissue to calculate the TBR. 
We confirmed these outcomes with MDSFR/SFF 
spectroscopy by correcting for tissue optical 
properties, although obtaining visual information 
from the fluorescence images is considered to be most 
clinically relevant for the for the intraoperative 
evaluation of the margin status since it provides 
wide-field information. 
Here, we studied single-dose cetuximab-800CW 
cohorts as well as cohorts pre-dosed with an 
unlabeled dose cetuximab followed by cetuximab- 
800CW. Although visualization of fluorescence was 
possible even in the lower single-doses cohorts, a 
clinically relevant discrimination between tumor and 
non-tumor tissue was obtained in the pre-dosed 
cohorts (Figure S6). Here, background fluorescence 
remained consistently low, while a dose-dependent 
increase was observed with in the single-dose cohorts, 
indicating off-target receptor saturation when 
pre-dosing. 
A previous study using 25 mg/m2 cetuximab- 
800CW showed that pre-dosing with 100 mg 
unlabeled cetuximab improves tumor visualization 
over 10 mg unlabeled cetuximab [31]. Another study 
using panitumumab-800CW showed no difference 
between pre-dosed and single dose cohorts [37]. In the 
current study, we used a two-to-threefold lower 
cetuximab-800CW dose than previously described, 
which might decrease the risk of toxicity and costs. 
Although it is likely that the total dose of cetuximab 
(i.e. 90 mg in the optimal dose cohort) is relevant for 
potential toxicities, this is still considerably lower than 
previously described [15,31]. Importantly, the lower 
dose of cetuximab-800CW did not influence our 
imaging results, because we used a highly sensitive 
fluorescence camera system optimized for 
IRDye800CW visualization, whereas Rosenthal et al. 
used a system optimized for Indocyanine Green 
visualization (peak absorption and emission 806 nm 
and 830 nm respectively) [31]. 
 In addition, this study demonstrates the added 
value of quantification of intrinsic fluorescence values 
through correcting for tissue scattering and 
absorption coefficients for verifying the optimal dose. 
When interpreting fluorescence imaging results, one 
should realize that, regardless of the biodistribution of 
a fluorescent tracer, fluorescence intensities are 
influenced by several factors, such as the tissue optical 
properties, ambient light, imaging distance and the 
sensitivity and dynamic range of the fluorescence 
camera [23,29,38,39]. Previous studies investigating 
EGFR-targeted imaging in HNC surgery solely used 
fluorescence visualization to report outcome 
parameters [15,22], although recently techniques have 
been described to quantify fluorescence [40]. Here, we 
demonstrate the added value of MDSFR/SFF 
spectroscopy in dose-finding studies, as we show the 
uncorrected fluorescence results differ 
significantly from corrected 
fluorescence values.  
The preliminary sensitivity and 
specificity of 100% and 91% respectively 
clearly demonstrate the potential added 
value of back-table FGI of the resection 
specimen for intraoperative clinical 
decision making, despite our limited 
patient sample. All tumor-positive 
resection margins had initially been 
missed by visual and tactile inspection. 
In the current study which involves 
fifteen patients, in four cases a 
tumor-positive resection margin was 
detected (4/15, 27%). There was no 
particular tumor-phenotypic feature 
that contributed to the missed positive 
 
 
Figure 5. Cetuximab-800CW binding specificity. Cetuximab-800CW fluorescence was located 
around the tumor cells, indicating specific binding. A Hoechst-DAPI staining was performed to visualize cell 
nuclei and the FITC channel was used to discriminate between autofluorescence and cetuximab-800CW 
derived fluorescence on the 800 nm channel. Abbreviations: H/E: Hematoxylin and Eosin. FITC: Fluorescein 
isothiocyanate. 





margins. In fact, all tumors were moderately 
differentiated squamous cell carcinomas ranging from 
T1 to T4 stages. Although we observed one 
false-positive fluorescent lesion on the resection 
margin, a high sensitivity is crucial in HNC treatment, 
as leaving residual tumor negatively influences 
treatment outcome and survival [4]. Back-table FGI 
serves as a ‘red-flag’ imaging technique that allows 
the surgeon to perform more targeted fresh frozen 
section analysis or to perform a re-resection while the 
patient is still anesthetized. This potentially prevents 
second surgery or (extensive) adjuvant treatment 
regimens. This is congruent with data from previous 
studies investigating the added value of back-table 
FGI [16,18]. The benefit of a specimen-driven 
approach for margin evaluation is that it can be 
performed in a controlled and standardized environ-
ment, which overcomes previously described factors 
that influence fluorescence imaging results [23].  
In the current study, we showed that it was 
feasible to perform FGI using a flexible nasendoscope 
which allowed imaging of locations that were difficult 
to assess using an open-surgery fluorescence camera. 
Although the fiber optic approach reduced imaging 
resolution and detection sensitivity compared to the 
wide-field fluorescence imaging system, we believe 
the nasendoscopic system can assist in detecting 
undisclosed lesions in the upper aerodigestive tract. 
EGFR was validated as a target using 
immunohistochemistry. Although we observed a 
heterogeneous EGFR expression in tumor tissue 
microscopically, this did not influence macroscopic 
fluorescence imaging results. In the current study, 
96% of HNSCC tissue sections expressed EGFR. 
Although the normal mucosa also expressed EGFR, 
this was not observed in the muscle, fat and 
connective tissue that forms the basal resection 
margin, where 80% of tumor-positive resection 
margins are located [9]. Although we observed EGFR 
expression in salivary glands which is in line with 
literature, this did no influence the evaluation of 
resection margins in the current study.  
In conclusion, we found that a dose of 75 mg 
unlabeled cetuximab followed by 15 mg 
cetuximab-800CW was well tolerated and allowed 
optimal discrimination between tumor and 
non-tumor tissue. MDSFR/SFF spectroscopy verifies 
the localization and quantifies the concentration of 
cetuximab-800CW in tumor and non-tumor tissue by 
correcting for tissue optical properties and provides 
important information on the tracer biodistribution, 
which supports our rationale for the optimal dose. 
The results of this study have led to the initiation of a 
currently ongoing phase-II clinical study in our 
institute (NCT03134846), investigating the clinical 
value of back-table FGI using cetuximab-800CW in a 
larger population of HNSCC patients.  
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